260 results
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
12 Mar 24
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
4:10pm
cartilage is avoided. Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head … was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL’s efficacy and safety in more than 2,000 patients with cancer. SUSTOL’s
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
24 Jan 24
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
8:01am
mammoplasty, and total shoulder arthroplasty. No unique safety issues were identified from the new clinical trials, and the bupivacaine and meloxicam … significantly less pain, with little to no opioid use.”
Important Safety Information for Patients
ZYNRELEF contains an NSAID (non-steroidal anti
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
11 Jan 24
Entry into a Material Definitive Agreement
4:07pm
arthroplasty surgical procedures. Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
14 Nov 23
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
4:10pm
for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. Safety … -based clinical studies that evaluated SUSTOL’s efficacy and safety in more than 2,000 patients with cancer. SUSTOL’s efficacy in preventing nausea
424B3
ywaimfmskbd8un1
5 Sep 23
Prospectus supplement
9:14pm
8-K
EX-99.1
sl8zea239dy0x0ift4kk
14 Aug 23
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
4:11pm
8-K
EX-10.1
s7jnx9nbc
24 Jul 23
Heron Therapeutics Announces $30 Million Private Placement Financing
9:12am
8-K
EX-99.1
rh41 qz3by
11 May 23
Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022
4:06pm
8-K
EX-99.1
amh51vpwff204u
20 Apr 23
Heron Therapeutics Announces Commercial Leadership Changes
9:10am
8-K
EX-99.1
qos97ru
29 Dec 22
Other Events
9:10am
8-K
EX-99.1
hptpxedzlt
8 Nov 22
Results of Operations and Financial Condition
4:10pm
424B5
xplq4 fzh2xvydfx1glk
20 Oct 22
Prospectus supplement for primary offering
4:06pm